1361390-56-8
1361390-56-8
Chemical Structure
RR-11a
- CAS No.: 1361390-56-8
- Formula:C24H28N6O10
- Molecular Weight:560.51
IUPAC Name: 2,5-dioxopyrrolidin-1-yl (E)-4-(1-(2-amino-2-oxoethyl)-2-(((benzyloxy)carbonyl)-L-alanyl-L-alanyl)hydrazinyl)-4-oxobut-2-enoate
InChIKey: OBTLSXIZYGMZRE-BWLFODOESA-N
SMILES: O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2
Biological Activity: RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RR-11a | 96.20% | RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73. [Content Brief]
- [2]. Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C
- [3]. Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11(11):1014. Published 2020 Nov 26. [Content Brief]
Keywords
